These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9241102)

  • 1. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction.
    Glue P; Sulowicz W; Colucci R; Banfield C; Pai S; Lin C; Affrime MB
    Br J Clin Pharmacol; 1997 Jul; 44(1):91-3. PubMed ID: 9241102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose pharmacokinetics of felbamate in the elderly.
    Richens A; Banfield CR; Salfi M; Nomeir A; Lin CC; Jensen P; Affrime MB; Glue P
    Br J Clin Pharmacol; 1997 Aug; 44(2):129-34. PubMed ID: 9278196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling.
    Banfield CR; Zhu GR; Jen JF; Jensen PK; Schumaker RC; Perhach JL; Affrime MB; Glue P
    Ther Drug Monit; 1996 Feb; 18(1):19-29. PubMed ID: 8848816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic drug monitoring of felbamate].
    Tribut O; Bentué-Ferrer D; Verdier MC;
    Therapie; 2010; 65(1):35-8. PubMed ID: 20205993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy.
    Sachdeo R; Narang-Sachdeo SK; Shumaker RC; Perhach JL; Lyness WH; Rosenberg A
    Epilepsia; 1997 Aug; 38(8):887-92. PubMed ID: 9579889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
    Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Felbamate: a new antiepileptic drug.
    Brodie MJ
    Lancet; 1993 Jun; 341(8858):1445-6. PubMed ID: 8099147
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.
    Graves NM; Ludden TM; Holmes GB; Fuerst RH; Leppik IE
    Pharmacotherapy; 1989; 9(6):372-6. PubMed ID: 2694113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamotrigine pharmacokinetics in patients receiving felbamate.
    Gidal BE; Kanner A; Maly M; Rutecki P; Lensmeyer GL
    Epilepsy Res; 1997 Apr; 27(1):1-5. PubMed ID: 9169285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential pharmacokinetic interaction between felbamate and phenobarbital.
    Gidal BE; Zupanc ML
    Ann Pharmacother; 1994 Apr; 28(4):455-8. PubMed ID: 8038465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy.
    Sachdeo RC; Narang-Sachdeo S; Montgomery PA; Shumaker RC; Perhach JL; Lyness WH; Rosenberg A
    J Clin Pharmacol; 1998 Feb; 38(2):184-90. PubMed ID: 9549651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Felbamate pharmacokinetics in the rat, rabbit, and dog.
    Adusumalli VE; Yang JT; Wong KK; Kucharczyk N; Sofia RD
    Drug Metab Dispos; 1991; 19(6):1116-25. PubMed ID: 1687019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction studies between felbamate and vigabatrin.
    Reidenberg P; Glue P; Banfield C; Colucci R; Meehan J; Rey E; Radwanski E; Nomeir A; Lim J; Lin C
    Br J Clin Pharmacol; 1995 Aug; 40(2):157-60. PubMed ID: 8562299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of felbamate in therapy for partial epilepsy in children.
    Carmant L; Holmes GL; Sawyer S; Rifai N; Anderson J; Mikati MA
    J Pediatr; 1994 Sep; 125(3):481-6. PubMed ID: 8071763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of felbamate on valproic acid disposition in healthy volunteers: inhibition of beta-oxidation.
    Hooper WD; Franklin ME; Glue P; Banfield CR; Radwanski E; McLaughlin DB; McIntyre ME; Dickinson RG; Eadie MJ
    Epilepsia; 1996 Jan; 37(1):91-7. PubMed ID: 8603632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involuntary movement disorders associated with felbamate.
    Kerrick JM; Kelley BJ; Maister BH; Graves NM; Leppik IE
    Neurology; 1995 Jan; 45(1):185-7. PubMed ID: 7824115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Felbamate: a new antiepileptic drug.
    Wagner ML
    Am J Hosp Pharm; 1994 Jul; 51(13):1657-66. PubMed ID: 7942890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Felbamate in epilepsy therapy: evaluating the risks.
    Pellock JM
    Drug Saf; 1999 Sep; 21(3):225-39. PubMed ID: 10487399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.
    Palmer KJ; McTavish D
    Drugs; 1993 Jun; 45(6):1041-1065. PubMed ID: 7691493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.